ChartRow logo
Data provided bySource: Twelve Data
ZLAB
$24.60-5.53%
as of close, Nov 13, 2026
☾ AH $24.60 -5.53%
Zai Lab Limited American Depositary SharesStock · HealthcareEmerging Markets · 0.02% of VWO
PeersONCSPYQQQNVDAAAPLMSFT
Share this page

ZLAB financial statements

The full income statement, balance sheet, and cash-flow statement for Zai Lab Limited American Depositary Shares (ZLAB), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.

Financial overview#

Revenue

5Y CAGR +56.5%5Y CAGR +56.5%YoY −6.8%
$441.7M TTM$108.2M Q3 '26
FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Gross profit

5Y CAGR +356.9%5Y CAGR +356.9%YoY +49.2%
— FY25— Q3 '26
FY18FY19FY20FY21FY22FY23FY24FY25
Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y n/m10Y n/mYoY n/m
−$278.3M TTM−$63M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

5Y n/m10Y n/mYoY n/m
−$198.4M TTM−$46.1M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y n/m5Y n/mYoY n/m
−$1.78 TTM−$0.40 Q3 '26
FY20FY21FY22FY23FY24FY25TTM
Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating cash flow

5Y n/m10Y n/mYoY n/m
−$159.2M TTM−$57.9M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Capital expenditure

5Y CAGR −4.4%5Y CAGR −4.4%YoY −68.5%
$4.1M TTM$947K Q3 '26
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y n/m5Y n/mYoY n/m
−$163.3M TTM−$58.8M Q3 '26
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Shares (diluted)

5Y +41.0%5Y +41.0%YoY +1.9%
111.3M TTM112.3M Q3 '26
FY20FY21FY22FY23FY24FY25TTM
Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Every ZLAB chart on Trends →

Shares outstanding (point-in-time)

2024-09 98.4M2024-12 107.8M2025-03 108.4M2025-06 109.9M2025-09 110.6M2025-12 110.6M2026-03 111.0M2026-06 112.2M2026-09 112.4M+14.2% over 8 periods

SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.

PeriodRangeOrderChangeFiguresAs-reported fiscal years.
Line itemTrendFY2025FY2024FY2023FY2022FY2021
Income Statementas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
Revenue460M+15.3%399M+49.6%267M+24.0%215M+49.0%144M+194.8%
——171M—91.9M+185.1%
Cost of revenue191M+29.5%147M+53.5%95.8M+29.4%74.0M+41.7%52.2M+212.1%
-690M-1.2%-681M-5.9%-643M-3.9%-619M+26.6%-844M-140.7%
Research & development221M-5.8%235M-11.8%266M-7.2%286M-50.0%573M+157.4%
Selling, general & administrative278M-7.1%299M+6.1%282M+8.7%259M+18.3%219M+96.6%
Amortization of intangibles5.90M+84.4%3.20M+357.1%700K+40.0%500K+0.0%500K+66.7%
Provision for credit losses6.00K-25.0%8.00K+33.3%6.00K+500.0%1.00K-90.0%10.0K+900.0%
Operating income-229M+18.7%-282M+23.0%-367M+9.3%-404M+42.2%-700M-132.0%
Interest expense5.21M+131.1%2.25M0.000.000.00-100.0%
Interest & investment income33.0M-10.9%37.1M-6.8%39.8M+172.9%14.6M+565.8%2.19M-57.2%
Other non-operating income3.54M-33.2%5.30M-24.4%7.01M+125.1%3.11M+130.5%-10.2M-237.5%
Equity-method income—0.000.00+100.0%-221K+79.1%-1.06M+5.5%
Gain (loss) on equity securities-1.91M+68.7%-6.11M-318.9%2.79M+131.2%-8.95M+38.8%-14.6M
Pre-tax income-178M+30.6%-257M+23.2%-335M+24.5%-443M+37.1%-704M-162.0%
Income tax-2.93M0.000.000.000.00
-176M+31.7%-257M+23.2%-335M+24.5%-443M+37.1%-704M-162.0%
Net income to common-176M+31.7%-257M+23.2%-335M+24.5%-443M+37.1%-704M-162.0%
-$1.60+38.5%-$2.60+25.7%-$3.50+23.9%-$4.60+39.5%-$7.60-117.1%
EPS (basic)-$1.60+38.5%-$2.60+25.7%-$3.50+23.9%-$4.60+39.5%-$7.60-117.1%
Weighted-avg shares (basic)110M+10.7%98.9M+2.4%96.6M+0.9%95.8M+3.0%93.0M+19.7%
Weighted-avg shares (diluted)110M+10.7%98.9M+2.4%96.6M+0.9%95.8M+3.0%93.0M+19.7%
Balance Sheetas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
1.02B-3.0%1.05B+11.8%940M-16.4%1.12B-25.1%1.50B+23.4%
Cash & equivalents680M+51.1%450M-43.1%790M-21.6%1.01B+4.6%964M+118.1%
Short-term investments10.0M-97.0%330M+1924.5%16.3M0.00-100.0%445M-40.2%
Accounts receivable106M+24.6%85.2M+43.9%59.2M+48.1%40.0M-15.8%47.5M+819.1%
Inventory74.7M+87.4%39.9M-11.0%44.8M+41.8%31.6M+66.9%19.0M+44.2%
Prepaid expenses36.7M-11.7%41.5M+80.6%23.0M-35.5%35.7M+98.0%18.0M+64.8%
1.17B-1.1%1.19B+14.4%1.04B-15.1%1.22B-24.2%1.61B+24.1%
Property, plant & equipment47.4M-1.2%48.0M-10.7%53.7M-7.1%57.9M+34.2%43.1M+47.8%
Operating lease right-of-use19.2M-10.9%21.5M+44.8%14.8M-23.9%19.5M+37.5%14.2M-19.8%
Intangible assets76.1M+35.9%56.0M+318.5%13.4M+786.1%1.51M-18.2%1.85M+20.6%
Long-term investments—3.12M-66.2%9.22M+43.4%6.43M-58.8%15.6M+1120.1%
Deferred tax assets3.39M0.00———
Other non-current assets3.05M-47.1%5.77M———
416M+39.0%299M+47.4%203M+45.2%140M-27.5%193M+96.8%
Accounts payable142M+40.3%101M-10.7%113M+71.3%66.0M-47.7%126M+101.4%
Short-term & current debt205M+55.3%132M0.00——
Current lease liability6.34M-21.2%8.05M+13.3%7.10M+0.8%7.05M+18.9%5.93M+13.8%
Other current liabilities63.7M+8.5%58.7M-29.2%83.0M+24.2%66.8M+9.9%60.8M+101.4%
457M+32.5%345M+43.6%240M+37.6%175M-24.1%230M+79.3%
Non-current lease liability13.4M-2.4%13.7M+70.4%8.05M-39.7%13.3M+38.8%9.61M-28.2%
Operating lease liability (total)19.7M-9.3%21.8M+43.6%15.2M-25.7%20.4M+31.2%15.5M-16.4%
Other non-current liabilities0.00-100.0%325K+0.0%325K0.00—
716M-14.9%841M+5.6%796M-23.9%1.05B-24.2%1.38B+18.0%
Common stock7.00K+0.0%7.00K+16.7%6.00K+0.0%6.00K+0.0%6.00K+20.0%
Additional paid-in capital3.34B+2.4%3.26B+9.7%2.98B+2.8%2.89B+2.4%2.83B+48.9%
Retained earnings-2.63B-7.2%-2.45B-11.7%-2.20B-18.0%-1.86B-31.3%-1.42B-98.7%
Treasury stock29.1M+39.4%20.8M+0.0%20.8M+75.7%11.9M+177.1%4.28M
Accumulated other comprehensive income29.7M-41.2%50.5M+34.3%37.6M+46.5%25.7M+208.6%-23.6M-62.8%
Total equity incl. non-controlling716M-14.9%841M+5.6%796M-23.9%1.05B-24.2%1.38B+18.0%
Total liabilities & equity1.17B-1.1%1.19B+14.4%1.04B-15.1%1.22B-24.2%1.61B+24.1%
Common shares issued111M+2.9%108M+10.8%97.7M+1.5%96.2M+0.7%95.5M+988.0%
Common shares outstanding111M+2.7%108M+10.8%97.2M+1.3%96.0M+0.5%95.5M+987.5%
Treasury shares7.43M+51.3%4.91M+0.0%4.91M+119.7%2.24M+484.0%383K
Cash Flowas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
-151M+29.8%-215M-8.4%-198M+46.1%-368M+33.1%-549M-154.2%
Depreciation & amortization15.0M+26.6%11.9M+31.3%9.03M+9.7%8.23M+26.8%6.49M+39.8%
Intangible amortization5.90M+84.4%3.20M+357.1%700K+40.0%500K+0.0%500K+66.7%
Share-based compensation65.6M-7.2%70.7M-11.3%79.6M+29.9%61.3M+50.6%40.7M+64.0%
Change in receivables18.9M-29.8%27.0M+34.6%20.0M+562.8%-4.33M-110.2%42.3M+2977.7%
Change in inventory47.0M+1307.1%-3.90M-126.1%14.9M-3.1%15.4M+114.4%7.17M+0.1%
Change in payables19.9M+1002.0%-2.21M-106.0%36.8M+168.4%-53.8M-184.7%63.5M+58.9%
308M+182.1%-375M-3381.7%-10.8M-102.6%420M+68.0%250M+145.1%
Capital expenditure8.10M+43.2%5.66M-21.6%7.21M-70.7%24.6M+34.4%18.3M+80.6%
Free cash flow-159M+27.9%-221M-7.4%-205M+47.6%-392M+30.9%-568M-150.9%
Acquisitions0.000.000.000.000.00
Proceeds from sale of PP&E87.0K+200.0%29.0K-76.2%122K0.00-100.0%3.00K
72.4M-79.3%350M+5539.0%-6.43M-271.8%-1.73M-100.2%820M-27.6%
Long-term debt issued0.000.000.000.000.00
Long-term debt repaid0.000.000.000.000.00
Common stock issued0.00-100.0%217M0.000.000.00
Common stock repurchased0.000.000.000.000.00
Dividends paid0.000.000.000.000.00
Net change in cash230M+195.6%-240M-10.3%-218M-591.3%44.4M-91.5%522M+42.5%
Interest paid4.88M+141.4%2.02M0.000.000.00-100.0%
Valuation Ratiosas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
Market cap1.95B-30.9%2.82B+6.6%2.65B-10.1%2.95B-50.9%6.00B+400.6%
P/S4.2×-40.0%7.1×-29.6%10.1×-32.9%15.0×-64.0%41.6×+69.8%
P/B2.7×-18.7%3.4×+11.7%3.0×+12.8%2.7×-38.7%4.3×+324.2%
Source filing10-K10-K10-K10-K10-K
Fiscal yearCEOTotal, as reportedActually paidOther executives, average$100 in the stock$100 in peers
FY2025Samantha (Ying) Du$10.7M$1.9M$3.8M$13.03$124.75
FY2024—$9.1M$12.1M$3.6M$19.35$93.49
FY2023—$12M$7.5M$3.9M$20.19$94.03
FY2022—$20.2M$739.6K$6.8M$22.68$89.90
FY2021—$15.3M−$30.5M$6.2M$46.44$100.02
FY2020—$8.5M$112.7M$3.4M——

From the pay-versus-performance table of each proxy statement (DEF 14A), the newest that states the year. “Actually paid” values stock awards at the year’s closing price, so it falls when the stock does. A year two chief executives shared lists each one’s pay, as reported / actually paid, and the totals are both. $100 in the stock and in the peer group the proxy names are the newest proxy’s, from the start of its first year.

About this data

Source: ZLAB’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all ZLAB filings on SEC EDGAR → Not investment advice.